Scientific World Model

What is the Scientific World Model?

Our AI agents have synthesized 17,000+ wiki-style pages covering every major entity, mechanism, and therapeutic avenue in neurodegeneration research. Each page is automatically generated and continuously updated from the latest scientific literature, connecting genes like APOE and MAPT to pathways, proteins, and disease mechanisms.

This forms a living knowledge graph that powers our hypothesis generation, therapeutic target identification, and research gap analysis. Browse by entity type below or search for any gene, protein, mechanism, or drug.

Showing 1–50 of 82 pages matching "AD"

🧪 PMN310 Anti-Amyloid for AD (NCT06750432)KG

clinical · 4,244 words · 51 hyp22 ana15 exp

🧪 Benfotiamine Phase 2 Alzheimer's Disease Trial (NCT06223360)KG

clinical · 3,941 words · 84 hyp24 ana56 exp

🧪 KarXT+EC Phase 3 (NCT07011732): Enhanced Formulation for AD AgitationKG

clinical · 3,402 words · 16 hyp6 ana1 exp

🧪 A 52-Week, Open-Label Extension Study of ACP-204 in Adults With Alzheimer's D... (NCT06194799)KG

clinical · 3,383 words · 9 hyp6 ana2 exp

🧪 Methylphenidate + iTBS for Apathy in AD (PRIME Trial)KG

clinical · 3,302 words · 49 hyp9 ana18 exp

🧪 CORT108297 Phase 2 (NCT04601038) - Stress Attenuation in ADKG

clinical · 3,284 words · 31 hyp9 ana4 exp

🧪 DBS Nucleus Basalis Trial (NCT07218081): Deep Brain Stimulation for ADKG

clinical · 3,187 words · 24 hyp19 ana14 exp

🧪 Cognitive Training to Reduce Incidence of Cognitive Impairment in Older Adults (NCT03848312)KG

clinical · 3,140 words · 13 hyp5 ana15 exp

🧪 Tricaprilin Phase 3 ALTER-AD Study (NCT05809908)KG

clinical · 3,109 words · 30 hyp4 ana5 exp

🧪 Safety and Clinical Outcomes Study: Amniotic and Umbilical Cord Tissue Admini... (NCT03899298)KG

clinical · 3,028 words · 8 hyp2 ana1 exp

🧪 XTR006 Tau PET for AD (NCT07115238)KG

clinical · 2,889 words · 12 hyp2 ana5 exp

🧪 Psilocybin for Depression in MCI/AD (NCT04123314)KG

clinical · 2,865 words · 8 hyp1 ana9 exp

🧪 Xanamem Phase 2 Alzheimer's Trial (NCT06125951)KG

clinical · 2,770 words · 7 hyp7 ana3 exp

🧪 AMDX-2011P Retinal Amyloid Tracer in Alzheimer's DiseaseKG

clinical · 2,654 words · 70 hyp27 ana61 exp

🧪 ARC-IM Adaptive Neurostimulation for Parkinson's DiseaseKG

clinical · 2,504 words · 29 hyp34 ana59 exp

🧪 TRAP-AD: Transcranial Photobiomodulation for Alzheimer's Disease (NCT04784416)KG

clinical · 2,497 words · 104 hyp58 ana53 exp

🧪 Noradrenergic Arousal System Phase 3 PD Trial (NCT07316296)KG

clinical · 2,493 words · 14 hyp8 ana2 exp

🧪 LY-3372689 MAGNOLIA Trial - Phase 2 in Alzheimer's DiseaseKG

clinical · 2,408 words · 69 hyp25 ana50 exp

🧪 Interleukin-2 Phase 2 (NCT06096090) — Immunomodulation for ADKG

clinical · 2,399 words · 20 hyp11 ana6 exp

🧪 KarXT (Xanomeline/Trospium) - Phase 3 for Alzheimer's Disease PsychosisKG

clinical · 2,356 words · 33 hyp21 ana48 exp

🧪 Longitudinal Multicenter Head-to-Head Harmonization of Tau PET Tracers (NCT05361382)KG

clinical · 2,136 words · 4 hyp1 ana2 exp

🧪 Dyadic Mindfulness for PD Carers (NCT06821230)KG

clinical · 2,037 words · 11 hyp18 exp

🧪 Advanced Rehabilitation Technologies in Corticobasal SyndromeKG

clinical · 2,036 words · 2 hyp4 ana

🧪 MK-1167 Phase 2 Alzheimer's Disease TrialKG

clinical · 1,969 words · 79 hyp25 ana55 exp

🧪 XTR006 Tau PET for Alzheimer's Disease (NCT07115238)KG

clinical · 1,922 words · 65 hyp25 ana52 exp

🧪 Citalopram Depression AD TrialKG

clinical · 1,881 words · 14 hyp3 ana4 exp

🧪 ARO-MAPT-SC Tau ASO Trial (NCT07221344) - Arrowhead PharmaceuticalsKG

clinical · 1,810 words · 18 hyp24 ana30 exp

🧪 RO7812653 for Early Symptomatic Alzheimer's DiseaseKG

clinical · 1,781 words · 69 hyp24 ana52 exp

🧪 LX1001 Phase 1/2 Trial (NCT03634007) - Gene Therapy for APOE4 Homozygote ADKG

clinical · 1,723 words · 58 hyp24 ana16 exp

🧪 Biomarker Validation Study for AD Combination TherapyKG

clinical · 1,676 words · 188 hyp56 ana33 exp

🧪 TTYP01 Phase 2 Alzheimer's Disease TrialKG

clinical · 1,652 words · 64 hyp25 ana51 exp

🧪 Fasudil for Early Alzheimer's Disease (FEAD) - NCT06362707KG

clinical · 1,562 words · 32 hyp21 ana49 exp

🧪 AMDX-2011P Phase 2 Trial for Alzheimer's DiseaseKG

clinical · 1,552 words · 67 hyp24 ana51 exp

🧪 NADAPT Study: NAD Replenishment Therapy for Atypical ParkinsonismKG

clinical · 1,489 words · 33 hyp20 ana17 exp

🧪 NCT07138677: MCI Network Guided TMS for Early Alzheimer's DiseaseKG

clinical · 1,478 words · 68 hyp26 ana63 exp

🧪 LX1001 Long-Term Follow-up (NCT05400330) - Gene Therapy for APOE4 Homozygote ADKG

clinical · 1,451 words · 52 hyp20 ana13 exp

🧪 RO7126209 (Brain Shuttle AD) Phase 1/2 Trial — NCT04639050KG

clinical · 1,406 words · 8 hyp23 ana1 exp

🧪 ONO-2020 for Alzheimer's Disease (NCT06881836)KG

clinical · 1,399 words · 40 hyp17 ana51 exp

🧪 Bilingualism Cognitive Reserve AD TrialKG

clinical · 1,384 words · 37 hyp4 ana9 exp

🧪 MK-1167 Phase 2 AD Trial (MK-1167-008)KG

clinical · 1,373 words · 29 hyp5 ana7 exp

🧪 Dexmedetomidine Transdermal System (DMTS) for AD AgitationKG

clinical · 1,335 words · 4 hyp3 ana14 exp

🧪 NCT07477431 - Levetiracetam for Persons at Risk for Alzheimer's DiseaseKG

clinical · 1,327 words · 44 hyp18 ana49 exp

🧪 Adaptive Deep Brain Stimulation to Offset STN Dysregulation During Exercise in Parkinson's Disease (NCT06296810)KG

clinical · 1,305 words · 3 hyp30 ana59 exp

🧪 AHEAD 3-45 Study: A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm,... (NCT04468659)KG

clinical · 1,296 words · 10 hyp1 ana1 exp

🧪 NCT07217665: PSP Clinical Trial Platform - Regimen A (AADvac1)KG

clinical · 1,278 words · 5 hyp4 ana8 exp

🧪 Self-administered tDCS for Parkinson's Disease GaitKG

clinical · 1,203 words · 7 hyp13 ana59 exp

🧪 Semaglutide EVOKE Plus (NCT04777409)KG

clinical · 1,155 words · 10 hyp24 ana19 exp

🧪 Adipose-Derived Mesenchymal Stem Cell Therapy for Early Alzheimer's Disease (NCT06775964)KG

clinical · 1,136 words · 69 hyp37 ana55 exp

🧪 VY7523 Phase 1/2 Alzheimer's Disease TrialKG

clinical · 1,123 words · 41 hyp21 ana48 exp

🧪 Gamma tACS for AD (NCT05326750)KG

clinical · 1,122 words · 7 hyp1 ana2 exp